Modulation of anxiety through blockade of anandamide hydrolysis
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The psychoactive constituent of cannabis, Δ9-tetrahydrocannabinol, produces in humans subjective responses mediated by CB1 cannabinoid receptors, indicating that endogenous cannabinoids may contribute to the control of emotion. But the variable effects of Δ9-tetrahydrocannabinol obscure the interpretation of these results and limit the therapeutic potential of direct cannabinoid agonists. An alternative approach may be to develop drugs that amplify the effects of endogenous cannabinoids by preventing their inactivation. Here we describe a class of potent, selective and systemically active inhibitors of fatty acid amide hydrolase, the enzyme responsible for the degradation of the endogenous cannabinoid anandamide. Like clinically used anti-anxiety drugs, in rats the inhibitors exhibit benzodiazepine-like properties in the elevated zero-maze test and suppress isolation-induced vocalizations. These effects are accompanied by augmented brain levels of anandamide and are prevented by CB1 receptor blockade. Our results indicate that anandamide participates in the modulation of emotional states and point to fatty acid amide hydrolase inhibition as an innovative approach to anti-anxiety therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“both serotonin and endocannabinoids are involved in stress-related phenotypes, such as anxiety (212).”
From Epigenetic Modifications in Stress Response Genes Associated With Childhood Trauma (2019) · cites this paper as [212]
In the citing paper
“the endogenous cannabinoids, such as anandamide, sleep-inducing substance oleamide (211) and palmitoylethanolamide (212), regulate numerous biological processes such as neuronal migration (213), learning, memory (214), pain processing (215), motility (216), and emotional-and reward-related processing (217–219).”
From Epigenetic Modifications in Stress Response Genes Associated With Childhood Trauma (2019) · cites this paper as [212]
In the citing paper
“Nabilone (Cesamet; Valeant Canada, Ltd., Montreal, Canada), an endocannabinoid receptor (CB 1 and CB 2 ) agonist, has been in use in Europe and Canada for over 25 years and was recently granted approval in the United States for the treatment of chemotherapy-induced nausea and vomiting.”
From The Use of a Synthetic Cannabinoid in the Management of Treatment‐Resistant Nightmares in Posttraumatic Stress Disorder (PTSD) (2009) · cites this paper as [12]
In the citing paper
“It has been well established that inhibition of FAAH, and elevation of AEA signaling, can significantly attenuate behavioral indices of fear and anxiety-related behavior in rodents.”
From The endocannabinoid system as a target for novel anxiolytic drugs (2017) · cites this paper as Kathuria et al., 2003
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125
Formation and inactivation of endogenous cannabinoid anandamide in central neurons
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C., & Piomelli, D. (1994) · Nature · doi:10.1038/372686a0 · Cited by 1,587
Self-citationMechanisms of emotional arousal and lasting declarative memory.
Cahill, L., & McGaugh, J. L. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01214-9 · Cited by 1,575
A second endogenous cannabinoid that modulates long-term potentiation
Stella, N., Schweitzer, P., & Piomelli, D. (1997) · Nature · doi:10.1038/42015 · Cited by 1,496
Self-citationBrain monoglyceride lipase participating in endocannabinoid inactivation
Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., Kathuria, S., & Piomelli, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152334899 · Cited by 1,373
Self-citationCravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
Cited by
Items 801–900 of 1,002
Thors, L., Alajakku, K., & Fowler, C. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707172 · Cited by 30
“URB597 has been shown to be very selective for FAAH (Kathuria et al., 2003, Clapper et al., 2006), but the effect of genistein upon FAAH in cell-free systems has not, to our knowledge, been tested.”
BackgroundMethodInfluentialAguilar, D. D., Chen, L., & Lodge, D. J. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu035 · Cited by 32
“URB597 is a FAAH inhibitor, which will potentiate endogenous AEA signaling (Kathuria et al., 2003).”
BackgroundModulators of Endocannabinoid Enzymic Hydrolysis and Membrane Transport
Ho, W. ‐. V., & Hillard, C. J. (2005) · Springer eBooks · doi:10.1007/3-540-26573-2_6 · Cited by 33
Wills, K. L., Vemuri, K., Kalmar, A., Lee, A., Limebeer, C. L., Makriyannis, A., & Parker, L. A. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3575-5 · Cited by 29
“3 mg/kg) and PF-3845 (10 mg/kg) were chosen on the basis of their ability to provide maximal inhibition of FAAH and concomitant elevation of AEA in rats when administered 2 h prior (Ahn et al. 2009; Fegley et al. 2005; Kathuria et al. 2003).”
InfluentialPillarisetti, S., Alexander, C. W., & Khanna, I. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.08.002 · Cited by 31
Heterocyclic sulfoxide and sulfone inhibitors of fatty acid amide hydrolase
Du, W., Hardouin, C., Cheng, H. W., Hwang, I., & Boger, D. L. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.10.025 · Cited by 31
Otrubova, K., Cravatt, B. F., & Boger, D. L. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401820q · Cited by 33
Chicca, A., Arena, C., & Manera, C. (2016) · Recent Patents on CNS Drug Discovery · doi:10.2174/1574889810999160603185126 · Cited by 31
“The growing pharmacological interest in generating potent and selective FAAH inhibitors is connected to the observation that increasing levels of AEA in the tissue potentiate the activity of the ECS leading to many beneficial effects, like analgesia, anti-depressant, anxiolytic and anti-inflammatory (15).”
BackgroundDefects in fatty acid amide hydrolase 2 in a male with neurologic and psychiatric symptoms
Sirrs, S., van Karnebeek, C. D., Peng, X., Shyr, C., Tarailo-Graovac, M., Mandal, R., Testa, D., Dubin, D., Carbonetti, G., Glynn, S. E., et al. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-015-0248-3 · Cited by 28
“hibitor [21,39], completely abolished AEA hydrolysis, thereby confirming that AEA hydrolysis observed in fibroblasts was mediated by FAAH2 (Figure 2G).”
BackgroundEndocannabinoid contributions to alcohol habits and motivation: Relevance to treatment
Gianessi, C. A., Groman, S. M., Thompson, S. L., Jiang, M., van der Stelt, M., & Taylor, J. R. (2019) · Addiction Biology · doi:10.1111/adb.12768 · Cited by 34
Dvořáková, M., Kubik‐Zahorodna, A., Straiker, A. J., Sedláček, R., Hájková, A., Mackie, K., & Blahoš, J. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15383 · Cited by 31
Gobira, P. H., de Aguiar, D. C., & Moreira, F. A. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.05.013 · Cited by 28
Kodani, S. D., Overby, H., Morisseau, C. H. P., Chen, J., Zhao, L., & Hammock, B. D. (2016) · Toxicology Letters · doi:10.1016/j.toxlet.2016.09.011 · Cited by 29
“Consistent with previous findings, URB597 is highly potent, with a low nanomolar IC50, and its potency increases significantly over time (an order of magnitude better between 5 and 60 min pre-incubation), as it forms a covalent complex with the enzyme (Kathuria et al., 2003).”
Backgroundn−3 polyunsaturated N-acylethanolamines are CB2 cannabinoid receptor-preferring endocannabinoids
Alharthi, N. S., Christensen, P. S., Hourani, W., Ortori, C. A., Barrett, D. A., Bennett, A. J., Chapman, V., & Alexander, S. P. H. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2018.08.003 · Cited by 31
Kind, L., & Kursula, P. (2018) · Amino Acids · doi:10.1007/s00726-018-2682-8 · Cited by 31
Fucich, E. A., Stielper, Z. F., Cancienne, H. L., Edwards, S., Gilpin, N. W., Molina, P. E., & Middleton, J. W. (2020) · Journal of Neurophysiology · doi:10.1152/jn.00570.2019 · Cited by 28
“3 mg/kg), JZL195 (16 mg/kg), or vehicle (1:1:18 solution of alcohol, emulphor, and saline) was administered by intraperitoneal injection 30 min after TBI procedures at doses that elicit maximal enzyme inhibition and behavioral effects in vivo (Kathuria et al. 2003; Long et al. 2009a, 2009b; Niphakis et al. 2013).”
BackgroundMethodEmotional, endocrine and brain anandamide response to social challenge in infant male rats
Marco, E. M., Scattoni, M. L., Rapino, C., Ceci, C., Chaves, N., Macrì, S., Maccarrone, M., & Laviola, G. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.04.004 · Cited by 30
“URB597 was administered at a dose of 0.1 mg/kg, i.p., 30 min before testing (Kathuria et al., 2003; Gobbi et al., 2005).”
Influentialde Lago, E., Gustafsson, S. B., Fernández‐Ruíz, J., Nilsson, J. A., Jacobsson, S. O. P., & Fowler, C. J. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04104.x · Cited by 29
“Combinations of URB597, CDC and indomethacin used concentrations of 1, 10 and 10 lM, respectively.”
ResultInfluentialSolinas, M., Tanda, G., Wertheim, C. E., & Goldberg, S. R. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1789-8 · Cited by 28
“…by dopamine agonists with the CB1-receptor antagonist rimonabant, and by enhancing the THC-like discriminative effects of D2 agonists with URB-597, an inhibitor of fatty acid amide hydrolase (FAAH), which prevents anandamide degradation and increases its levels in the brain (Kathuria et al. 2003).”
BackgroundJaiswal, S., Tripathi, R. K. P., & Ayyannan, S. R. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.125 · Cited by 27
Nader, J., Rapino, C., Gennequin, B., Chavant, F., Francheteau, M., Makriyannis, A., Duranti, A., Maccarrone, M., Solinas, M., & Thiriet, N. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.03.014 · Cited by 31
“We then investigated whether THC, the main psychoactive ingredient of cannabis extracts, or synthetic compounds like URB597, a selective inhibitor of the fatty acid amide hydrolase that increases the in vivo levels of AEA (Kathuria et al., 2003), and JZL184, a selective inhibitor of the monoacylglycerol lipase that in…”
BackgroundMethodSelf-citationA role for oleoylethanolamide in chronic lymphocytic leukemia
Masoodi, M., Lee, E., Eiden, M. J., Bahlo, A., Shi, Y., Ceddia, R. B., Baccei, C. S., Prasit, P., & Spaner, D. (2014) · Leukemia · doi:10.1038/leu.2014.10 · Cited by 27
Melis, M., & Pistis, M. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.03.009 · Cited by 28
Targeting the endogenous cannabinoid system to treat neuropathic pain
Lau, B. K., & Vaughan, C. W. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00028 · Cited by 30
“One promising idea would be to inhibit both FAAH and MAGL (Pertwee, 2013).”
BackgroundInfluentialHayase, T. (2007) · BMC Neuroscience · doi:10.1186/1471-2202-8-76 · Cited by 27
“With respect to these CBs, the anxiolytic effects except for those provided by AEA [29] have not been examined sufficiently.”
BackgroundEx Vivo Imaging of Fatty Acid Amide Hydrolase Activity and Its Inhibition in the Mouse Brain
Glaser, S. T., Gatley, S. J., & Gifford, A. N. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.094748 · Cited by 26
“ABBREVIATIONS: CB1R, cannabinoid receptor 1; 2-AG, 2-arachidonoyl glycerol; FAAH, fatty acid amide hydrolase; KO, knockout; WT, wild type; MGL, monoacylglycerol lipase; URB597, 3 -carbamoyl-biphenyl-3-yl-cyclohexylcarbamate; OL-135, 1-oxo-1[5-(2-pyridyl)-2-yl]-7-phenylheptane; AM404, N-(4 hydroxyphenyl)-arachidonamide…”
BackgroundInfluentialSimei, J. L. Q., Souza, J. D. R., Pedrazzi, J. F. C., Guimarães, F. S., Campos, A. C., Zuardi, A. W., Hallak, J. E. C., & Crippa, J. A. S. (2024) · Pharmaceuticals · doi:10.3390/ph17121644 · Cited by 32
Benson, N., Metelkin, E., Demin, O. O., Li, G., Nichols, D., & van der Graaf, P. (2014) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.72 · Cited by 28
Kruk-Słomka, M., Banaszkiewicz, I., Słomka, T., & Biała, G. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1596-0 · Cited by 26
Bouter, Y., Brzózka, M. M., Ryguła, R., Pahlisch, F., Boost, C., Leweke, F. M., Havemann‐Reinecke, U., & Rohleder, C. (2019) · Cannabis and Cannabinoid Research · doi:10.1089/can.2019.0041 · Cited by 31
“Several pre-clinical studies also showed that stress inhibits AEA signaling.(70,71) Therefore, it could be argued that a pharmacological intervention using ECs could be a promising strategy for treating anxiety disorders.”
Janković, M., Spasojević, N., Ferizović, H., Stefanović, B., & Dronjak, S. (2020) · Physiology & Behavior · doi:10.1016/j.physbeh.2020.113174 · Cited by 31
Schiavi, S., Manduca, A., Carbone, E., Buzzelli, V., Rava, A., Feo, A., Ascone, F., Morena, M., Campolongo, P., Hill, M. N., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01454-7 · Cited by 27
Lee, T. T.-Y., Hill, M. N., Hillard, C. J., & Gorzalka, B. B. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.021 · Cited by 26
Forster, L., Elfringhoff, A. S., & Lehr, M. (2009) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-009-2850-5 · Cited by 27
Vilela, L., Medeiros, D. D. C., de Oliveira, A. C. P., Moraes, M. F. D., & Moreira, F. A. (2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12232 · Cited by 32
Palmer, J. A., Higuera, E. S., Chang, L., & Chaplan, S. R. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.04.047 · Cited by 28
Öz, M., Jaligam, V., Galadari, S., Petroianu, G. A., Шуба, Я. М., & Shippenberg, T. S. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06557.x · Cited by 26
“In addition to PMSF, we tested 1 lM URB597, a specific and potent FAAH inhibitor (Kathuria et al. 2003), and the cyclooxygenase inhibitor, indomethacin (5 lM) to further investigate the involvement of AEA hydrolysis products in AEA regulation of hDAT (Fig.”
MethodRibeiro, A. B., Ferraz-de-Paula, V., Pinheiro, M. L., & Palermo‐Neto, J. (2009) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2009000600013 · Cited by 26
“A similar effect was observed after administration of URB597, an inhibitor of fatty acid amide hydrolase (9,10).”
BackgroundEmbryonic diapause in humans: time to consider?
Ptak, G., Modlinski, J. A., & Loi, P. (2013) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-11-92 · Cited by 26
“AEA participates in the modulation of emotions and anxiety [18].”
BackgroundBrose, S. A., Golovko, S. A., & Golovko, M. Y. (2016) · Lipids · doi:10.1007/s11745-016-4144-y · Cited by 28
Human serum albumin: A modulator of cannabinoid drugs
Leboffe, L., di Masi, A., Trezza, V., Polticelli, F., & Ascenzi, P. (2017) · IUBMB Life · doi:10.1002/iub.1682 · Cited by 28
“Among them are worthy of mention: (i) the FAAH inhibitors URB597 ([3-(3-carbamoylphenyl)phenyl]-N-cyclohexylcarbamate; PubChem CID: 1383884) (Table 1) (12) and AM5206 (1,1,1-trifluoro-4-(4-phenylmethoxyphenoxy)butan-2-one; PubChem CID: 102 336706) (Table 1), which inhibit AEA hydrolysis (13), (ii) the MAGL inhibitor J…”
BackgroundCharacterization of biotin-anandamide, a novel tool for the visualization of anandamide accumulation
Fezza, F., Oddi, S., Tommaso, M. D., Simone, C. D., Rapino, C., Pasquariello, N., Dainese, E., Finazzi‐Agrò, A., & Maccarrone, M. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m700486-jlr200 · Cited by 30
Chronic Pain and the Endocannabinoid System: Smart Lipids – A Novel Therapeutic Option?
Zieglgänsberger, W., Brenneisen, R., Berthele, A., Wotjak, C. T., Bandelow, B., Tölle, T. R., & Lutz, B. (2022) · Medical Cannabis and Cannabinoids · doi:10.1159/000522432 · Cited by 25
Synthesis and Evaluation of Paracetamol Esters As Novel Fatty Acid Amide Hydrolase Inhibitors
Onnis, V., Congiu, C., Björklund, E., Hempel, F., Söderström, E., & Fowler, C. J. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901891p · Cited by 28
A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase
Gattinoni, S., Simone, C. D., Dallavalle, S., Fezza, F., Nannei, R., Battista, N., Minetti, P., Quattrociocchi, G., Caprioli, A., Borsini, F., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.06.050 · Cited by 25
Effects of Acute Stress on Cardiac Endocannabinoids, Lipogenesis, and Inflammation in Rats
Holman, E. A., Guijarro, A. I., Lim, J., & Piomelli, D. (2013) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000025 · Cited by 25
“, immune, endocrine, and cardiovascular) (8) and regulates glucose/lipid metabolism to conserve and store energy (e.”
BackgroundResultSelf-citationOrchestrated activation of mGluR5 and CB1 promotes neuroprotection
Batista, E. M., Doria, J. G., Ferreira-Vieira, T. H., Alves‐Silva, J., Ferguson, S. S. G., Moreira, F. A., & Ribeiro, F. M. (2016) · Molecular Brain · doi:10.1186/s13041-016-0259-6 · Cited by 26
Analgesic effects of FAAH inhibitor in the insular cortex of nerve-injured rats
Kim, M. J., Tanioka, M., Um, S. W., Hong, S., & Lee, B. H. (2018) · Molecular Pain · doi:10.1177/1744806918814345 · Cited by 29
“Although the activity of TRPV1 sustains and induces pain,(70) the calcium ion influx mediated by this channel in the cannabinoid signaling pathway may prompt NAPE-PLD synthesis, which leads to the production of AEA and the reduction of pain.(71) In order to confirm our hypothesis, reduced levels of NAPE-PLD expression…”
BackgroundEndogenous cannabinoid modulation of restraint stress‐induced analgesia in thermal nociception
Atwal, N., Winters, B. L., & Vaughan, C. W. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14884 · Cited by 26
A high throughput fluorescent assay for measuring the activity of fatty acid amide hydrolase
Kage, K., Richardson, P. L., Traphagen, L. M., Severin, J. M., Pereda‐Lopez, A., Lubben, T. W., Davis‐Taber, R., Vos, M. H., Bartley, D. M., Walter, K. A., et al. (2006) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2006.10.006 · Cited by 25
Scalable synthesis of oleoyl ethanolamide by chemical amidation in a mixed solvent
Wang, X., Han, Z., Chen, Y., Jin, Q., & Wang, X. (2015) · Journal of the American Oil Chemists Society · doi:10.1007/s11746-015-2749-6 · Cited by 25
Wang, D., Lin, Q. D., Kang, K., Wu, Y., Su, S., & Hai, J. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4431 · Cited by 24
Anxiolytic effects of endocannabinoid enhancing compounds: A systematic review and meta-analysis
Kwee, C., Leen, N. A., der Kamp, R. C. V., Lissa, C. J. V., Cath, D. C., Groenink, L., & Baas, J. M. P. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.04.001 · Cited by 28
Simone, J. J., Malivoire, B. L., & McCormick, C. M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.08.032 · Cited by 25
Oxidative Metabolism of a Fatty Acid Amide Hydrolase-Regulated Lipid, Arachidonoyltaurine
Vaught, M., Kingsley, P. J., Rouzer, C. A., Cravatt, B. F., & Marnett, L. J. (2008) · Biochemistry · doi:10.1021/bi702530z · Cited by 24
Tichenor, M. S., Keith, J. M., Jones, W. M., Pierce, J. M., Merit, J. E., Hawryluk, N. A., Seierstad, M. J., Palmer, J. A., Webb, M., Karbarz, M. J., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.10.076 · Cited by 26
Neuroanatomical substrates involved in cannabinoid modulation of defensive responses
Moreira, F. A., Aguiar, D., Resstel, L. B. M., Lisboa, S. F. D. S., Campos, A. C., Gomes, F. V., & Guimarães, F. S. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111400651 · Cited by 27
“In these studies AEA uptake/metabolism inhibitors also induced anxiolytic-like effects (Lisboa et al., 2008; Resstel et al., 2008d), consistent with the effects observed after systemic administration (Kathuria et al., 2003; Moreira et al., 2008).”
BackgroundCarnevali, L., Vacondio, F., Rossi, S., Macchi, E., Spadoni, G., Bedini, A., Neumann, I. D., Rivara, S., Mor, M., & Sgoifo, A. (2015) · Scientific Reports · doi:10.1038/srep18218 · Cited by 27
Self-citationCooperative enzymatic control of N-acyl amino acids by PM20D1 and FAAH
Kim, J. T., Terrell, S. M., Li, V. L., Wei, W., Fischer, C. R., & Long, J. Z. (2020) · eLife · doi:10.7554/elife.55211 · Cited by 24
Alteba, S., Portugalov, A., Hillard, C. J., & Akirav, I. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.12.022 · Cited by 27
Enhancement of endocannabinoid signaling protects against cocaine-induced neurotoxicity
Vilela, L., Gobira, P. H., Viana, T. G., Medeiros, D. D. C., Ferreira-Vieira, T. H., Doria, J. G., Rodrigues, F. G., de Aguiar, D. C., Pereira, G. S., Massensini, A. R., et al. (2015) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.04.013 · Cited by 24
“Specific compounds have been developed to inhibit this enzyme and facilitate endocannabinoid signaling (Kathuria et al., 2003).”
Butler, R. K., Ford, G. K., Hogan, M., Roche, M., Doyle, K., Kelly, J. P., Kendall, D. A., Chapman, V., & Finn, D. P. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111413823 · Cited by 29
Inhibitors of monoacylglycerol lipase as novel analgesics
Hohmann, A. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707153 · Cited by 24
“…of fatty-acid amide hydrolase (FAAH), an enzyme which catalyzes anandamide hydrolysis (Cravatt et al., 1996), have been evaluated for their therapeutic potential for suppressing pain, anxiety and stress-related responses in preclinical studies (Kathuria et al., 2003; Hohmann et al., 2005).”
BackgroundClapper, J. R., Duranti, A., Tontini, A., Mor, M., Tarzia, G., & Piomelli, D. (2006) · Pharmacological Research · doi:10.1016/j.phrs.2006.06.008 · Cited by 24
“The selectivity of URB597 for FAAH is supported by n vitro studies, which have shown that this compound has o effect on a variety of serine hydrolase activities, includng human and electric-eel acetylcholinesterase, horse plasma utyryl cholinesterase and rat brain monoacylglycerol lipase MGL) [8].”
BackgroundInfluentialSelf-citationBjörklund, E., Norén, E., Nilsson, J., & Fowler, C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00974.x · Cited by 30
“…FAAH1, Alexander et al., 2009), and selective inhibitors of this enzyme such as URB597 (3′-(aminocarbonyl)[1,1′biphenyl]-3-3-yl)-cyclohexylcarbamate, Kathuria et al. 2003) have shown potentially useful activity in models of pain, inflammation, anxiety and depression (see, e.g. Kathuria et al.,…”
BackgroundArnold, J. C., Dielenberg, R. A., & McGregor, I. S. (2010) · Life Sciences · doi:10.1016/j.lfs.2010.09.018 · Cited by 23
Assay and inhibition of diacylglycerol lipase activity
Johnston, M., Bhatt, S. R., Sikka, S., Mercier, R. W., West, J. M., Makriyannis, A., Gatley, S. J., & Duclos, R. I. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.05.101 · Cited by 23
Watabiki, T., Tsuji, N., Kiso, T., 徹, 小., Narazaki, F., & Kakimoto, S. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.007 · Cited by 24
“Our results for ASP8477 is in line with the reports that other FAAH inhibitors showed no sedation nor abnormal behaviors (Kathuria et al., 2003; Ahn et al., 2011).”
BackgroundResultInfluentialTransient receptor potential vanilloid 1 channels modulate the anxiolytic effect of diazepam
Manna, S. S. S., & Umathe, S. N. (2011) · Brain Research · doi:10.1016/j.brainres.2011.09.049 · Cited by 25
Search for monoglyceride lipase inhibitors: synthesis and screening of arylthioamides derivatives
Kapanda, C. N., Muccioli, G. G., Labar, G., Draoui, N., Lambert, D. M., & Poupaert, J. H. (2008) · Medicinal Chemistry Research · doi:10.1007/s00044-008-9123-2 · Cited by 23
“As endocannabinoids are biosynthesized upon demand, by inhibiting FAAH or MGL their effect could be enhanced in a more physiological manner when compared with the administration of synthetic cannabinoids (Jayamanne et al., 2006; Kathuria et al., 2003).”
BackgroundThe Pharmacology of the Cannabinoid System—A Question of Efficacy and Selectivity
Fowler, C. J. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0001-6 · Cited by 25
“OL-135 (1-oxo-1[5-(2-pyridyl)-2-yl]-7-phenylheptane) [93, 94], both of which inhibit FAAH at nanamolar concen-”
BackgroundMeyers, M. J., Long, S. A., Pelc, M. J., Wang, J. L., Bowen, S. J., Walker, M. C., Schweitzer, B. A., Madsen, H. M., TenBrink, R. E., McDonald, J. J., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.08.055 · Cited by 23
The endocannabinoid system in gp120-mediated insults and HIV-associated dementia
Bari, M., Rapino, C., Mozetic, P., & Maccarrone, M. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.03.025 · Cited by 23
“, 2008), and genetic depletion of the faah gene or pharmacological inhibition of intracellular FAAH activity result in elevated CNS levels of AEA (Cravatt et al., 2001; Fegley et al., 2005; Kathuria et al., 2003).”
Development of Fragment‐Based n‐FABS NMR Screening Applied to the Membrane Enzyme FAAH
Lambruschini, C., Veronesi, M., Romeo, E., Garau, G., Bandiera, T., Piomelli, D., Scarpelli, R., & Dalvit, C. (2013) · ChemBioChem · doi:10.1002/cbic.201300347 · Cited by 23
Self-citationModulation of the endocannabinoid system: Therapeutic potential against cocaine dependence
Tanda, G. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.09.001 · Cited by 26
“Solinas M, Justinova Z, Goldberg SR, Tanda G. Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats.”
BackgroundInfluentialContarini, G., Ferretti, V., & Papaleo, F. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00787 · Cited by 22
Ando, T., Tamura, N., Mera, T., Morita, C., Takei, M., Nakamoto, C., Koide, M., Hotta, M., Naruo, T., Kawai, K., et al. (2014) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.69 · Cited by 24
“CB1R mediates many actions of AEA such as its effects on appetite, food intake (Berry and Mechoulam 2002), emotion (Martin et al. 2002; Kathuria et al. 2003), and pain (Lichtman et al. 2004).”
BackgroundInfluentialHaller, J., Aliczki, M., Gyimesi-Pelczer, K., Spitzer, K., Balogh, Z., & Kántor, S. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3273-8 · Cited by 22
“At this time point, 0.3 mg/kg URB597 has a maximal effect on brain anandamide, which is increased about threefold over basal levels (Kathuria et al. 2003; Piomelli et al. 2006).”
InfluentialTemporal changes in mouse brain fatty acid amide hydrolase activity
Glaser, S. T., & Kaczocha, M. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.06.043 · Cited by 21
Labar, G., Vliet, F. V., Wouters, J., & Lambert, D. M. (2007) · Amino Acids · doi:10.1007/s00726-007-0540-1 · Cited by 22
“…protein Fatty acid amide hydrolase belongs to the recently discovered endocannabinoid system, and the therapeutical potential of this membrane-bound protein is currently explored, notably since its inhibition was reported to induce analgesia and anxiolysis in rodents (Kathuria et al., 2003).”
BackgroundInfluentialCannabinoids in Health and Disease
Meccariello, R., & Chianese, R. (2016) · InTech eBooks · doi:10.5772/61595 · Cited by 22
Anandamide modulation of circadian- and stress-dependent effects on rat short-term memory
Santori, A., Colucci, P., Mancini, G. F., Morena, M., Palmery, M., Trezza, V., Puglisi‐Allegra, S., Hill, M. N., & Campolongo, P. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.06.018 · Cited by 24
Self-citationMarzo, V. D., Ligresti, A., Morera, E., Nalli, M., & Ortar, G. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.07.026 · Cited by 22
Kury, L. T. A., Voitychuk, O. I., Ali, R. M., Galadari, S., Yang, K. S., Howarth, F. C., Шуба, Я. М., & Öz, M. (2014) · Cell Calcium · doi:10.1016/j.ceca.2013.12.005 · Cited by 22
Cat odour-induced anxiety—a study of the involvement of the endocannabinoid system
Sütt, S., Raud, S., Areda, T., Reimets, A., Kõks, S., & Vasar, E. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0927-4 · Cited by 25
“It is interesting to note that the inhibitors of FAAH have been shown to increase exploratory behaviour and reduce anxiety in rodents (Kathuria et al. 2003; Rutkowska et al. 2006).”
BackgroundAaltonen, N., Kędzierska, E., Orzelska‐Górka, J., Lehtonen, M., Navia‐Paldanius, D., Jakupović, H., Savinainen, J. R., Nevalainen, T., Laitinen, J. T., Parkkari, T., et al. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.233114 · Cited by 25
“In the tetrad test, FAAH inhibitors generally induce analgesia but no cannabimimetic side effects (Kathuria et al., 2003; Long et al., 2009c), whereas dual inhibition of both MAGL and FAAH has been reported to induce all four tetrad effects (Long et al., 2009c).”
BackgroundLipid rafts: A nexus for endocannabinoid signaling?
McFarland, M. J., & Barker, E. L. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.05.010 · Cited by 22
Wyffels, L., Bruyne, S. D., Blanckaert, P., Lambert, D. M., & Vos, F. D. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.11.019 · Cited by 26
Siegmund, S., Wojtalla, A., Schlosser, M., Zimmer, A., & Singer, M. V. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.06.033 · Cited by 22
Wang, L., Yui, J., Wang, Q., Zhang, Y., Mori, W., Shimoda, Y., Fujinaga, M., Kumata, K., Yamasaki, T., Hatori, A., et al. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00248 · Cited by 22
Bosier, B., Muccioli, G. G., & Lambert, D. M. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02208.x · Cited by 23
“Among drugs eliciting such an inhibition, URB597 is a prime candidate as it elevates AEA levels in the rat and mouse brain (Kathuria et al., 2003; Tarzia et al., 2003) and magnifies its action through a selective blockade of FAAH activity (Fegley et al., 2005).”
BackgroundInfluentialLimebeer, C. L., Abdullah, R. A., Rock, E. M., Imhof, E., Wang, K., Lichtman, A. H., & Parker, L. A. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3282-7 · Cited by 21
“Neither FAAH nor MAGL inhibitors induce the cataleptic behavioral reactions evident with direct CB 1 agonists (Kathuria et al. 2003; Long et al. 2009b), and FAAH inhibitors are inactive in animal models of drug abuse (Gobbi et al. 2005).”
BackgroundVacondio, F., Silva, C., Lodola, A., Carmi, C., Rivara, S., Duranti, A., Tontini, A., Sanchini, S., Clapper, J. R., Piomelli, D., et al. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.07.021 · Cited by 23
“Piomelli D, Tarzia G, Duranti A, Tontini A, Mor M, Compton TR, Dasse O, Monaghan EP, Parrott JA, Putman D. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597).”
InfluentialSelf-citationBjörklund, E., Blomqvist, A., Hedlin, J., Persson, E., & Fowler, C. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103479 · Cited by 21
Metabolomics of fescue toxicosis in grazing beef steers
Mote, R. S., Hill, N. S., Uppal, K., Tran, V., Jones, D. P., & Filipov, N. M. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.04.020 · Cited by 21
Effects of centrally administered endocannabinoids and opioids on orofacial pain perception in rats
Zubrzycki, M., Janecka, A. E., Liebold, A., Ziegler, M., & Zubrzycka, M. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13970 · Cited by 25
“PEA and OEA are capable of elevating levels of AEA through substrate competition at FAAH (Kathuria et al., 2003; Alhouayek and Muccioli, 2014).”
BackgroundFantauzzi, M. F., Aguiar, J. A., Tremblay, B. J.-M., Mansfield, M. J., Yanagihara, T., Chandiramohan, A., Revill, S. D., Ryu, M. H., Carlsten, C., Ask, K., et al. (2020) · ERJ Open Research · doi:10.1183/23120541.00128-2020 · Cited by 27
“Additional genes and proteins implicated to be involved in cannabis-associated disorders and novel cannabinoid based therapeutic approaches were included and described in annotated table format (Table 1)[23-26, 38-60].”
Kondev, V., Winters, N. D., & Patel, S. (2021) · International review of neurobiology · doi:10.1016/bs.irn.2020.09.007 · Cited by 24
PET Imaging of Fatty Acid Amide Hydrolase with [18F]DOPP in Nonhuman Primates
Rotstein, B. H., Wey, H., Shoup, T. M., Wilson, A. A., Liang, S. H., Hooker, J. M., & Vasdev, N. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500316h · Cited by 23
Age-Dependent Relevance of Endogenous 5-Lipoxygenase Derivatives in Anxiety-Like Behavior in Mice
Leo, L. M., Almeida-Corrêa, S., Canetti, C. D. A., Amaral, O. B., Bozza, F. A., & Pamplona, F. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085009 · Cited by 21
“We hypothesized that if 5-LO inhibition reduces AEA effects in the brain, mice treated with 5-LO inhibitors would show increased anxiety-like behavior, similarly to what occurs with mice treated with CB1 receptor antagonists [4] and contrary to what occurs after enhancement of AEA levels by URB597 [5].”
Metadata
- Authors
- Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., Giustino, A., Tattoli, M., Palmery, M., Cuomo, V., & Piomelli, D.
- Affiliations
- University of California, Irvine (US)
- University of Urbino (IT)
- University of Parma (IT)
- University of Naples Federico II (IT)
- University of Bari Aldo Moro (IT)
- Sapienza University of Rome (IT)
- Corresponding author
- Piomelli, Daniele
- ORCID
- Venue
- Nature Medicine
- Published
- 2002-12-02
- Volume
- 9
- Issue
- 1
- Pages
- 76-81
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4241363254
- Cited by
- 1,293
- References
- 45
- Citations by year
- 2026: 10 · 2025: 23 · 2024: 25 · 2023: 35 · 2022: 34 · 2021: 32 · 2020: 48 · 2019: 45 · 2018: 35 · 2017: 45 · 2016: 59 · 2015: 76 · 2014: 66 · 2013: 72 · 2012: 70
- FWCI
- 29.07
- Type
- journal article
- Language
- en
- Open access
- green
- escholarship.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- CINECA IRIS Institutional Research information system (University of Urbino) (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
- Keywords
- anandamide, fatty acid amide hydrolase inhibition, anxiety, CB1 receptor, endocannabinoids, anxiolytics, benzodiazepine-like effects, elevated zero maze
- MeSH terms
- Rimonabant, Fatty Acid Amide Hydrolases, Amidohydrolases, Animals, Anxiety, Arachidonic Acids, Behavior, Animal, Cannabinoids, Cells, Cultured, Dose-Response Relationship, Drug, Humans, Neurons, Piperidines, Pyrazoles, Radioligand Assay, Receptors, Drug, Anti-Anxiety Agents, Vocalization, Animal, Molecular Structure, Rats, Wistar, Receptors, Cannabinoid, Rats, Polyunsaturated Alkamides, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.